Boehringer Ingelheim
R & D Technologies
Site Map
Contact
Home
State-of-the-art: Boehringer Ingelheim’s R & D approaches and techniques

Boehringer Ingelheim's successful drug discovery also relies on excellent interdisciplinary cooperation and well-functioning medicinal chemistry with state-of-the-art

combinatorial chemistry chemoinformatics diversified chemical library efficient biopharmaceutical development.

Technologies and approaches such as genomics, proteomics, bioinformatics, e-R & D, ultra high-throughput screening and modern galenical and device development are today vital for successful Research & Development.

Targeting new territory - genomics, proteomics, bioinformatics, e-R & D, Ultra high-throughput screening

e-R & D - Mastering the data flood

Ultra high-throughput screening
Ultra high-throughput screening, as testing system, allows up to 100,000 tests to be performed per day.

Combinatorial chemistry
New imaging techniques to analyse tests, further reduction in size of titre plates, reduction in amount of substance required and new technologies for data evaluation including artifical intelligence, comprise the next steps in development to further modernize screening of substance pools and substance libraries compiled by means of combinatorial chemistry.

 
 
Interesting Links

Up

 

© 1999 Boehringer Ingelheim GmbH, Germany. All rights reserved. 
Imprint | Terms of use  

Last update: 08.04.2008